157 related articles for article (PubMed ID: 10561307)
1. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors.
Ahmed FY; Johnston SJ; Cassidy J; O'Kelly T; Binnie N; Murray GI; van Gennip AH; Abeling NG; Knight S; McLeod HL
J Clin Oncol; 1999 Aug; 17(8):2439-45. PubMed ID: 10561307
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
Heslin MJ; Yan J; Weiss H; Shao L; Owens J; Lucas VS; Diasio RB
Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
[TBL] [Abstract][Full Text] [Related]
3. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
[TBL] [Abstract][Full Text] [Related]
8. Clinical development of eniluracil: current status.
Hohneker JA
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):52-6. PubMed ID: 9830627
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
[TBL] [Abstract][Full Text] [Related]
10. Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.
Leichman CG; Chansky K; Macdonald JS; Doukas MA; Budd GT; Giguere JK; Abbruzzese JL;
Invest New Drugs; 2002 Nov; 20(4):419-24. PubMed ID: 12448660
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of fluorinated pyrimidines: eniluracil.
Baker SD
Invest New Drugs; 2000 Nov; 18(4):373-81. PubMed ID: 11081573
[TBL] [Abstract][Full Text] [Related]
12. Oral eniluracil/5-FU for advanced colon and breast carcinomas.
Benson AB
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):57-63; discussion 64. PubMed ID: 11219979
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Meropol NJ; Niedzwiecki D; Hollis D; Schilsky RL; Mayer RJ;
Cancer; 2001 Apr; 91(7):1256-63. PubMed ID: 11283924
[TBL] [Abstract][Full Text] [Related]
14. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Schilsky RL; Kindler HL
Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
[TBL] [Abstract][Full Text] [Related]
15. Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer.
Uetake H; Ichikawa W; Takechi T; Fukushima M; Nihei Z; Sugihara K
Clin Cancer Res; 1999 Oct; 5(10):2836-9. PubMed ID: 10537350
[TBL] [Abstract][Full Text] [Related]
16. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action.
Saleem A; Yap J; Osman S; Brady F; Suttle B; Lucas SV; Jones T; Price PM; Aboagye EO
Lancet; 2000 Jun; 355(9221):2125-31. PubMed ID: 10902627
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
[TBL] [Abstract][Full Text] [Related]
18. Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
van Staveren MC; Opdam F; Guchelaar HJ; van Kuilenburg AB; Maring JG; Gelderblom H
Cancer Chemother Pharmacol; 2015 Jul; 76(1):47-52. PubMed ID: 25957957
[TBL] [Abstract][Full Text] [Related]
19. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer.
Johnston SJ; Ridge SA; Cassidy J; McLeod HL
Clin Cancer Res; 1999 Sep; 5(9):2566-70. PubMed ID: 10499634
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of two fluorouracil administration regimens for colorectal cancer.
Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]